$SLNO

Halper Sadeh LLC investigates four major M&A deals—involving $MKC, $OMEX, $SLNO, $FORA—alleging insider favoritism and inadequate shareholder protections.

Halper Sadeh LLC investigates $AVNS, $LEG, $SLNO, $FORA acquisitions, examining whether shareholders receive fair consideration and fiduciary duties are upheld.

Portnoy Law Firm launches class action against $SLNO for allegedly concealing safety issues with lead drug DCCR, citing 27% stock plunge following patient death disclosure.

Rosen Law Firm recruits investors with $100K+ losses in $SMCI securities class action alleging false statements and concealed export law violations. Lead plaintiff deadline: May 26, 2026.

Rosen Law Firm recruits $EOSE investors with $100K+ losses for class action over alleged false production statements. Lead plaintiff deadline: May 5, 2026.

Rosen Law Firm urges Soleno Therapeutics investors with $100K+ losses to join securities lawsuit alleging concealed DCCR drug safety concerns. Lead plaintiff deadline: May 5, 2026.

Class action filed against $SLNO for allegedly failing to disclose safety concerns about DCCR drug. Stock fell sharply after August 2025 short report and September patient death disclosure.

Three companies face securities class action suits alleging material misstatements. Investors must apply by May 18, 2026 for $GEMINI; earlier deadlines for $SLNO and $NAVAN.

Law firm files class action against $ENPH for allegedly overstating inventory management and financial prospects during 2025.

Halper Sadeh investigates four companies' mergers, questioning whether shareholders received fair deals and adequate disclosures in transactions involving Soleno, Forian, McCormick, and Cyclerion.

Class action lawsuit filed against $SLNO for allegedly concealing safety concerns and patient death related to experimental drug DCCR, causing significant shareholder losses.

Eos Energy Enterprises faces shareholder securities class action alleging false statements about production capacity and battery performance, with May 5, 2026 deadline for investor claims.

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors have until May 5, 2026 deadline to join lawsuit.

Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9B in all-cash deal, paying $53/share—a 34% premium driven by Soleno's FDA-approved Vykat XR for Prader-Willi Syndrome.

Soleno Therapeutics faces class action lawsuit alleging failure to disclose material DCCR drug safety concerns, including excess fluid retention in clinical trials that reduced commercial viability.

Neurocrine acquires Soleno for $2.9B to gain Vykat XR, a rare disease blockbuster generating $190M in 2025 revenue.

Rosen Law Firm alerts $SLNO investors about class action lawsuit alleging false statements regarding DCCR drug safety. Lead plaintiff deadline: May 5, 2026.

Federal class action filed against $SLNO over alleged safety misrepresentations of DCCR drug. Stock fell 39% after safety revelations; investor deadline May 5, 2026.

Law firm Kahn Swick & Foti files class action against $ENPH alleging financial misstatements; April 20, 2026 deadline for lead plaintiff applications.

Kahn Swick & Foti, LLC filed class action suits against Gemini Space Station over alleged cryptocurrency platform misstatements. Investors must apply by May 18, 2026.